Cargando…
Clinical efficacy and safety of statins in managing cardiovascular risk
Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understandi...
Autores principales: | Kapur, Navin K, Musunuru, Kiran |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496987/ https://www.ncbi.nlm.nih.gov/pubmed/18561510 |
Ejemplares similares
-
Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
por: Musunuru, Kiran
Publicado: (2010) -
Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
por: Goldenberg, Naila, et al.
Publicado: (2009) -
Moving toward genome-editing therapies for cardiovascular diseases
por: Musunuru, Kiran
Publicado: (2022) -
The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis
por: Zhu, Yunyun, et al.
Publicado: (2020) -
High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
por: Kapur, Navin K, et al.
Publicado: (2008)